Decoy Therapeutics Inc
Company Profile
Business description
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
Contact
2450 Holcombe Boulevard
Suite X
HoustonTX77021
USAT: +1 713 913-5608
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Chart of the Week: China demand for copper falls amidst record rally
stocks
Reporting season was stronger than share prices suggest
stocks
How Anthropic makes money—and what investors should know ahead of its IPO filing
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,198.30 | 37.90 | 0.41% |
| CAC 40 | 8,262.72 | 17.91 | -0.22% |
| DAX 40 | 25,912.47 | 73.14 | 0.28% |
| Dow JONES (US) | 53,061.95 | 295.07 | 0.56% |
| FTSE 100 | 10,829.05 | 72.60 | 0.67% |
| HKSE | 25,213.31 | 97.90 | -0.39% |
| NASDAQ | 26,217.83 | 118.05 | 0.45% |
| Nikkei 225 | 64,214.48 | 111.16 | -0.17% |
| NZX 50 Index | 13,846.18 | 84.39 | -0.61% |
| S&P 500 | 7,666.60 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,020.10 | 46.10 | 0.51% |
| SSE Composite Index | 3,942.09 | 0.70 | 0.02% |